In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

Rhea-AI Summary

N2OFF (NASDAQ: NITO) highlighted a peer‑reviewed study co‑authored by Prof. Ciro Leonardo Pierri on SLC25A mitochondrial carriers as biomarkers and therapeutic targets for spaceflight‑induced dysfunction. The December 30, 2025 Journal of Translational Medicine article examined 53 SLC25A genes and used AAC3 as a structural case study.

The research aligns with MitoCareX Bio's focus and its MITOLINE™ platform for virtual modeling and small‑molecule discovery targeting mitochondrial carriers.

News Market Reaction

-7.14%

4 alerts

-7.14% News Effect

+11.0% Peak Tracked

-14.8% Trough Tracked

-$269K Valuation Impact

$3M Market Cap

0.1x Rel. Volume

On the day this news was published, NITO declined 7.14%, reflecting a notable negative market reaction. Argus tracked a peak move of +11.0% during that session. Argus tracked a trough of -14.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $269K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

SLC25A genes analyzed: 53 genes Study publication date: December 30, 2025 DOI: 10.1186/s12967-025-07505-z +4 more

7 metrics

SLC25A genes analyzed 53 genes Transcriptomic data from NASA OSDR under spaceflight stressors

Study publication date December 30, 2025 Journal of Translational Medicine online publication

DOI 10.1186/s12967-025-07505-z Reference for spaceflight mitochondrial carrier study

Ownership in MitoCareX Bio 100% N2OFF’s stake in MitoCareX Bio Ltd.

Solar projects 4 projects Lead investor role across European Union solar assets

EU countries 3 countries Geographic spread of N2OFF’s solar projects

Stake in Save Foods approximately 98% Ownership of Save Foods Ltd. share capital

Market Reality Check

Price: $0.9100 Vol: Volume 59,504 is far belo...

low vol

$0.9100 Last Close

Volume Volume 59,504 is far below the 20-day average of 2,462,450, indicating little pre-news positioning. low

Technical Shares at $1.26 are trading below the 200-day MA of $6.26 and about 97.5% under the 52-week high.

Peers on Argus

Peers show mixed moves: SEED up 2.36%, AVD up 2.21%, while BIOX is down 12.76% a...

Peers show mixed moves: SEED up 2.36%, AVD up 2.21%, while BIOX is down 12.76% and ENFY down 6.67%. No clear, unified sector trend appears around this biotech-focused announcement.

Historical Context

5 past events · Latest: Jan 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 22	Preclinical data update	Positive	+9.7%	In vitro MITOLINE™ candidates reduced pro‑inflammatory markers in human immune cells.
Jan 15	Scientific research focus	Positive	+5.4%	Highlighted peer‑reviewed study on SLC25A mitochondrial carriers under spaceflight stress.
Jan 05	Solar project economics	Positive	+0.0%	Advanced $340,000 to improve economics, citing about $1.7M added project profit stake.
Dec 29	Renewable value unlock	Positive	-19.4%	Reported de‑risking and ~$1.69M savings across German and Italian renewable projects.
Nov 18	Acquisition & pipeline	Positive	+0.7%	Closed MitoCareX acquisition and outlined hit compounds and 2026 preclinical plans.

Pattern Detected

Positive MitoCareX and renewable energy updates often saw aligned gains, but some value-unlock news drew weak or negative reactions, indicating inconsistent market confidence.

Recent Company History

Over recent months, N2OFF has pivoted around two pillars: MitoCareX Bio’s mitochondrial‑targeted drug discovery and European renewable energy projects. News on MitoCareX’s hit compounds and in vitro anti‑inflammatory data generated modest positive moves, while earlier spaceflight‑related mitochondrial research also coincided with gains. In contrast, solar project de‑risking and value‑unlock announcements saw flat to negative reactions. Today’s article again emphasizes MitoCareX’s scientific depth rather than near‑term financial changes, fitting the pattern of R&D‑driven narratives.

Market Pulse Summary

The stock moved -7.1% in the session following this news. A negative reaction despite science-focuse...

Analysis

The stock moved -7.1% in the session following this news. A negative reaction despite science-focused news fits prior episodes where value-building announcements, such as European renewable milestones, saw selling pressure up to -19.37%. The current article emphasizes academic validation of mitochondrial carrier biology, not cash flow or de‑risking. Weak confidence in long-term execution or balance-sheet concerns could have overshadowed the technical merits of the research, given the stock’s position far below its 52-week high.

Key Terms

microgravity, cosmic radiation, transcriptomic, osteocytes, +4 more

8 terms

microgravity medical

"spaceflight conditions, including microgravity and cosmic radiation."

Microgravity is a condition where objects experience almost no net weight because they are in continuous free-fall, such as aboard orbiting spacecraft; think of passengers feeling weightless in a smoothly falling elevator. For investors, microgravity matters because it enables scientific experiments and manufacturing processes that behave very differently than on Earth, potentially creating novel drugs, materials, or technologies, changing development timelines, costs, market opportunities and regulatory considerations.

cosmic radiation medical

"spaceflight conditions, including microgravity and cosmic radiation."

High-energy particles and rays from space that strike Earth’s atmosphere and can penetrate aircraft, spacecraft, electronic equipment and human tissue. For investors, cosmic radiation matters because it can damage satellites and sensitive electronics, increase maintenance or liability costs for airlines and space firms, and create regulatory or health-related risks that affect revenue and capital spending—much like rust slowly wearing down metal infrastructure.

transcriptomic medical

"The work integrates transcriptomic data from NASA's Open Science Data Repository"

Transcriptomic describes anything related to the transcriptome — the complete set of RNA messages a cell or tissue makes at a given time, which shows which genes are actively being used. Think of it like a snapshot of which recipes are being cooked in a kitchen; for investors, transcriptomic data matters because it helps identify drug targets, predict treatment response, and validate whether a therapy is affecting biology as intended, all of which can change a company’s development prospects and valuation.

osteocytes medical

"expression of 53 SLC25A genes in osteocytes, human bone marrow-derived"

Osteocytes are the most common cells inside bone, embedded like maintenance workers within the hard tissue; they sense stress or damage and send signals that tell the bone to repair, strengthen, or thin. Investors track osteocytes because many diagnostics and drugs for osteoporosis, fracture healing and other bone conditions work by changing those signals, so understanding osteocyte biology helps predict clinical trial outcomes, regulatory decisions and market demand for related therapies.

mesenchymal stem cells medical

"human bone marrow-derived mesenchymal stem cells (hBMSCs), and mouse brain tissue"

Mesenchymal stem cells are adult cells that can develop into bone, cartilage, fat and other connective tissues and act like a versatile repair crew in the body. Investors watch them because they are the basis for many experimental therapies and regenerative medicines: successful clinical results could create large markets, while manufacturing complexity, safety concerns and regulatory hurdles make development costly and risky.

mitochondrial carriers medical

"SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets"

Mitochondrial carriers are proteins that act like tiny ferry boats or gatekeepers, moving key molecules—such as energy sources, building blocks and waste—across the membrane of mitochondria, the cell’s power plants. They matter to investors because changes or drugs that affect these carriers can underlie diseases, serve as biomarkers, or become targets for therapies and diagnostics, influencing the valuation and risk of biotech and pharma investments.

adp/atp carrier medical

"the ADP/ATP carrier AAC3 was further examined as a structural case study"

The ADP/ATP carrier is a protein in the inner membrane of mitochondria that acts like a cellular turnstile, exchanging ATP (the cell’s usable energy packet) produced inside the mitochondrion for ADP (the spent form) from the rest of the cell. It matters to investors because its function influences cell energy balance and survival, making it a potential drug target and biomarker for metabolic diseases, cancer and toxicity studies—areas that can affect R&D priorities, regulatory risk and company value.

bioenergetics medical

"targeted to rescue mitochondrial bioenergetics under stress."

Bioenergetics is the study of how living cells generate, store and use energy—think of cells as tiny engines or batteries that power all biological functions. For investors, it matters because therapies, diagnostics or products that change how cells manage energy can create new markets or disrupt existing ones, affecting a company’s revenue potential, development costs and regulatory risks in sectors like biotech, pharmaceuticals and agriculture.

AI-generated analysis. Not financial advice.

Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.

The study, titled “SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier (AAC3) as a structural case study,” was published online on December 30, 2025 (DOI: 10.1186/s12967-025-07505-z). The work integrates transcriptomic data from NASA's Open Science Data Repository (OSDR), examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells (hBMSCs), and mouse brain tissue exposed to microgravity and spaceflight-related stressors.

The analysis identified differential regulation of multiple SLC25A carriers under spaceflight conditions, supporting their potential utility as biomarkers of mitochondrial and metabolic dysfunction.

The ADP/ATP carrier AAC3 was further examined as a structural case study, based on comparative modeling and structure–function analyses to illustrate how carrier conformational features may be targeted to rescue mitochondrial bioenergetics under stress.

While this independent academic research- conducted in collaboration with the University of Bari “Aldo Moro” and the University of Pittsburgh—was not performed under MitoCareX Bio's auspices, it directly aligns with the Company's core scientific area of focus on mitochondrial carrier biology. MitoCareX Bio applies proprietary approaches, including the MITOLINE^™ algorithm to virtually model, screen and validate small-molecule modulators targeting the SLC25A family of mitochondrial carriers. These proteins, central to cellular energy metabolism, play central roles in hard-to-treat indications including in several types of cancer, metabolic diseases related to the metabolic syndrome, and are also implicated in rare inherited disorders associated with neuromuscular degeneration, which share mechanistic similarities with physiologicl alterations observed in astronauts.

Prof. Ciro Leonardo Pierri's expertise in structural biology, mitochondrial carriers and drug targeting- demonstrated through his contributions to this and other related publications- underpins the foundational science driving MitoCareX Bio's precision pipeline.

The full article is available open access at: https://doi.org/10.1186/s12967-025-07505-z.

About N2OFF Inc:

N2OFF owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer and inflammatory metabolic diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build ) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd

N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.

For more information, please visit www.n2off.com.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements in this communication may include, among other things, statements about N2OFF’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or products and its future results, operations and financial performance and condition. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including market conditions as well as those discussed under the heading “Risk Factors” in N2OFF’s Annual Report on Form 10-K filed with the SEC on March 31, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

FAQ

What did N2OFF (NITO) highlight about the December 30, 2025 study on SLC25A carriers?

The company highlighted a peer‑reviewed study identifying differential regulation of 53 SLC25A genes under spaceflight conditions. According to the company, the article uses AAC3 as a structural case study and aligns with MitoCareX Bio's drug discovery focus on mitochondrial carriers.

How does the AAC3 structural case study relate to MitoCareX Bio's drug discovery approach (NITO)?

AAC3 was examined to show how carrier conformations may be targeted to restore mitochondrial bioenergetics. According to the company, this structural analysis illustrates concepts used by MitoCareX Bio and its MITOLINE™ algorithm for virtual screening of small‑molecule modulators.

Does the published research perform experiments under MitoCareX Bio's auspices (NITO)?

No, the research was independent and conducted with academic collaborators at University of Bari and University of Pittsburgh. According to the company, the work nonetheless directly aligns with MitoCareX Bio's scientific focus on mitochondrial carrier biology.

Where can investors read the full Journal of Translational Medicine article mentioned by N2OFF (NITO)?

The full article is open access and available via DOI 10.1186/s12967-025-07505-z published online December 30, 2025. According to the company, the paper is accessible through the journal's website and public scientific repositories.

What is the investor significance of N2OFF's (NITO) mention of MITOLINE™ and mitochondrial carrier targets?

The company emphasizes that MITOLINE™ models and screens small molecules against SLC25A carriers central to energy metabolism. According to the company, this technology underpins MitoCareX Bio's precision pipeline targeting cancer, metabolic and rare neuromuscular disorders.